Keywords: Vertex, Financial outlook, Researc h, Telaprevir, Cystic fibrosis, Rheumatoid arthritis, Epilepsy, Merck & Co, Boceprevir

Vertex maintains 2010 outlook, reveals launch plan for hep C drug telaprevir and progress of other programs

Article | 11 January 2011

Print This

The USA’s Vertex Pharmaceuticals (Nasdaq: VRTX) yesterday announced its 2011 business objectives in conjunction with the 29th Annual JP ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in